{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:30:30Z","timestamp":1791232230416,"version":"4.1.0"},"reference-count":15,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2005,8]]},"abstract":"<jats:p><jats:bold>Summary:\u2002<\/jats:bold>  <jats:italic>Purpose:<\/jats:italic> Epilepsy is a major public\u2010health problem in Africa. The quality of available drugs is a limiting factor for an adequate management. The aim of this study was to describe the proportion of poor\u2010quality phenobarbital (PB) solid\u2010dosage forms and evaluate the factors associated with its quality in Nouakchott (Mauritania).<\/jats:p><jats:p> <jats:italic>Methods:<\/jats:italic> A cross\u2010sectional study was carried out within pharmacies, hospitals, and on the parallel market in March 2003. PB samples were bought by a native person and then assayed by a liquid chromatography method. A package was considered to be of good quality if the active\u2010substance average content was between 85 and 115% of the stated content printed on the packet.<\/jats:p><jats:p> <jats:italic>Results:<\/jats:italic> Forty\u2010five pharmaceutical stores were visited, enabling us to collect 146 samples of PB. Three brand names were available in Nouakchott. They originated from France, Morocco, Senegal, and Egypt.<\/jats:p><jats:p> <jats:italic>Results:<\/jats:italic> A prevalence of 13.7%[95% confidence interval (CI), 8.8\u201320.0] of poor\u2010quality PB was found. All samples from Morocco were underdosed. The generic active content was satisfactory, but saccharose, an excipient with a potential side effects, was identified. Two factors associated with the good quality of PB have been put forward: tablets manufactured in France and loose packaging as generics conditioned in such a way were of good quality.<\/jats:p><jats:p> <jats:italic>Conclusions:<\/jats:italic> This study shows that the quality of antiepileptic drugs in Africa is still worrying. The setting up of medicine quality control in Mauritania is legitimate. Considering the good quality of generic PB and its lower cost, this type of medicine should be promoted in this region.<\/jats:p>","DOI":"10.1111\/j.1528-1167.2005.01805.x","type":"journal-article","created":{"date-parts":[[2005,8,2]],"date-time":"2005-08-02T01:50:15Z","timestamp":1122947415000},"page":"1293-1296","source":"Crossref","is-referenced-by-count":28,"title":["Quality of Phenobarbital Solid\u2010dosage Forms in the Urban Community of Nouakchott (Mauritania)"],"prefix":"10.1111","volume":"46","author":[{"given":"Marie\u2010Laure","family":"Laroche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidou","family":"Traore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Merle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Michel","family":"Gaulier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marylene","family":"Viana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre\u2010Marie","family":"Preux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,8]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(04)00963-9"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.32800.x"},{"key":"e_1_2_6_4_2","first-page":"344","article-title":"The treatment of epilepsy in developing countries: where do we go from here?","volume":"79","author":"Scott RA","year":"2001","journal-title":"Bull WHO"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92620-8"},{"key":"e_1_2_6_6_2","first-page":"59","article-title":"Counterfeit drugs: implications for health","volume":"11","author":"Ten Mam M","year":"1992","journal-title":"Adverse Drug React Toxicol Rev"},{"key":"e_1_2_6_7_2","volume-title":"Counterfeit and substandard drugs in Myanmar and Vietnam","author":"Wondemagegnehu E","year":"1999"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.1997.d01-403.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)05065-0"},{"key":"e_1_2_6_10_2","article-title":"La qualit\u00e9 des m\u00e9dicaments sur le march\u00e9 pharmaceutique africain: \u00e9tude analytique dans 3 pays: Cameroun, Madagascar, Tchad","author":"REMED\/OMS","year":"1995","journal-title":"WHO\/DAP"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(00)00265-X"},{"key":"e_1_2_6_12_2","volume-title":"European pharmacopeia","year":"2002"},{"key":"e_1_2_6_13_2","article-title":"Le secteur pharmaceutique priv\u00e9 commercial au Maroc","author":"WHO","year":"1997","journal-title":"WHO\/DAP"},{"key":"e_1_2_6_14_2","volume-title":"Harrison's principles of internal medicine","author":"Fauci AS","year":"1998"},{"key":"e_1_2_6_15_2","first-page":"323","article-title":"A comparative bioavailability of four carbamazepine tablet formulations available in the Kenya market","volume":"73","author":"Oluka MO","year":"1996","journal-title":"East Afr Med J"},{"key":"e_1_2_6_16_2","first-page":"815","article-title":"Traitement des \u00e9pileptiques en milieu rural au Mali","volume":"158","author":"Farnarier G","year":"2002","journal-title":"Rev Neurol"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2005.01805.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2005.01805.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T16:32:31Z","timestamp":1697128351000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2005.01805.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["10.1111\/j.1528-1167.2005.01805.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2005.01805.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}